Naibec, Promotes Expansion in Chinese Market for Implant Materials

Naibec is pushing to expand its supply volume to the Chinese market following its direct entry into the U.S. market.

Naibec announced on the 24th that it has been selected for a government project supporting clinical trials in China. With this government support, diversification of implant material products for the Chinese market is expected to be possible. Separately, negotiations with Straumann for increased volume of existing product lines are also being considered. The company plans to actively respond to the implant markets in the U.S. and China, the world's largest implant markets, to increase the supply of core implant materials.

Naibec was finally selected in the 'Overseas Clinical Trial Division' of the 'Innovative Medical Device Company Technology Commercialization Support Project' led by the Ministry of Health and Welfare. Receiving research support worth 1.5 billion KRW from the government, Naibec plans to conduct clinical trials in China on 'OCS-B Collagen,' one of the core implant materials. The company explained that OCS-B Collagen, which is a specially processed collagen fused with the bone graft material 'OCS,' helps maintain the volume of bone defects while perfectly supporting implant placement when applied to bone defect areas.

The clinical trial will be conducted at four hospitals in China?Wuhan University Stomatological Hospital, Nanjing University Department of Stomatology, Nanjing Medical University, and Xi'an Jiaotong University Stomatological Hospital?applying OCS-B Collagen to a total of 192 patients and observing efficacy and adverse effects over 24 weeks.

If the clinical results prove safety and efficacy at leading public hospitals in China, the recognition of OCS-B Collagen in the Chinese market is expected to rise. Naibec has also filed a Chinese patent for the manufacturing technology of OCS-B Collagen, establishing a strong entry barrier.

So far, Naibec has completed clinical trials in China for the implant bone graft material 'OCS-B' and the periodontal tissue regeneration material 'Guidos' membrane. OCS-B received sales approval from the Chinese National Medical Products Administration (NMPA) in 2020 and is currently being sold in the Chinese market. The Guidos membrane also applied for sales approval from the Chinese NMPA last May and is awaiting approval.

A Naibec representative said, "With government clinical support, the commercialization of OCS-B Collagen in China will accelerate significantly. We will rapidly commercialize OCS-B Collagen and build a diverse lineup of implant bio-materials together with the already marketed bone graft material (OCS-B) and the soon-to-be-approved Guidos membrane, expanding sales in the Chinese market."

He added, "We expect to succeed in diversifying our product portfolio for entry into the Chinese market through this government project selection. Sales of existing core bone regeneration materials for implants have been steadily supplied to the global market, and overseas sales, including China, are expected to increase significantly in the second half of the year."

This content was produced with the assistance of AI translation services.